Contact Verastem, Inc.
Brian Sullivan, 617-252-9314
CAMBRIDGE, MA – Sep. 10, 2013 – Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib). COMMAND is a registration-directed trial of lead cancer stem cell inhibitor […]
Recently, we had the honor to interview Melissa Culligan, RN, BSN, MS, a thoracic surgery nurse with specialized experience designing clinical trials. To listen press PLAY in the above podcast box (it may take a minute for the podcast to load).
In a cancer like mesothelioma, for which there is only one FDA-approved treatment, clinical trials […]
Last night, Dr. Tobias Peikert of the Mayo Clinic joined us on a conference call, as part of the Meso Foundation’s Meet the Experts series, to discuss an exciting new clinical trial. The trial, which uses the measles virus to attack the mesothelioma cells, is currently enrolling pleural mesothelioma patients regardless of whether they’ve undergone prior therapy. […]
by Lee M. Krug, MD
At the International Mesothelioma Interest Group Meeting in Boston, a group of investigators convened at a Clinical Trials Design Workshop to discuss the challenges of conducting trials in this disease. The rarity of mesothelioma poses various issues with regards to proper study design, accrual, and interest by pharmaceutical companies. One theme […]
Tonight, as part of the “Meet the Experts” podcasts presented exclusively by the Meso Foundation, Dr. Julie Brahmer, Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, sat down with Mary Hesdorffer, Nurse Practitioner and Medical Liaison for the Meso Foundation, to discuss her new trial targeting pleural mesothelioma. […]